Allied Health & Imaging · Independent exam preparation
CBGC Certification Examination Study Guide
Practise pedigree risk, disorder recognition, test selection, variant interpretation and client-centred decisions across all nine CBGC domains for Canadian CCGC examination preparation.
By CertMedbry · Updated 31 October 2026
Calculate conditional genetic risks, recognise representative genetic disorders, select tests by the changes they detect, and explain results in ways that support informed decisions. These 60 concepts connect mechanisms to practical Canadian genetic counselling cases. They provide selective preparation across all nine domains; the official CBGC Exam Content Outline defines the full examinable scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and credential does this guide address?
The CBGC Certification Examination is the Canadian examination associated with Canadian Certified Genetic Counsellor, abbreviated CCGC, or the French designation CGAC. ABGC separately awards Certified Genetic Counselor, CGC®, through its own examination. These credentials and examinations are not interchangeable.
How many questions are there, and how long is the examination?
CBGC's general information describes approximately 150 multiple-choice questions over three hours. The 20 questions here are independent four-option learning drills and do not predict examination performance.
CBGC — Introduction, Application Pathways and General Information
What delivery arrangements and examination date are verified?
The certification page, checked on October 30, 2026, lists February 18, 2027, and describes the 2027 examination as online and remotely proctored. Candidates should use CBGC's examination-day information for operational requirements and subsequent updates.
Which outline version applies, and what changed in 2025?
The currently linked Exam Content Outline identifies its content as updated June 2018, version 2, and its name as updated December 2025. It was formerly called Knowledge-Based Competencies. The December 2025 change is a document-name update, not evidence of a new content revision or effective syllabus date. CBGC states that its examination uses the most recent outline.
CBGC — Exam Preparation Materials · CBGC — Exam Content Outline
Are official domain percentages available?
CBGC states that examination areas receive unequal weighting according to current practice, but the consulted outline and general information do not publish numerical percentages. This guide therefore uses an editorial allocation across all nine domains, with additional breadth in inheritance, clinical assessment and test interpretation. Its allocation is not an official weighting.
CBGC — Introduction, Application Pathways and General Information · CBGC — Exam Content Outline
Why is Unit 9 called Genetic Counselling here?
The English outline repeats the Prenatal Diagnosis heading for Unit 9, while its French heading is Conseil génétique. Competencies 9.1–9.8 address ethics, counselling, communication, histories, grief, culture and legal issues. Genetic Counselling is used here to identify that substantive domain while preserving awareness of the heading discrepancy.
How do eligibility pathways relate to this preparation guide?
CBGC has multiple application pathways, but this guide addresses the shared Canadian examination rather than selecting an eligibility pathway for a candidate. The certification page announces changes with different implementation dates, including future changes for the 2028 application window and a regulation-dependent Pathway E. Eligibility requires CBGC application approval; meeting pathway criteria alone is not an approval decision.
This independent guide addresses the Canadian CBGC Certification Examination leading to CCGC. The separate ABGC examination awards CGC®. The 2025 Canadian core competencies inform professional context; the currently linked CBGC Exam Content Outline remains the scope reference.
Outline used: Verified against the currently linked CBGC Exam Content Outline: content updated June 2018, version 2; document name updated December 2025. Reviewed 2026-10-13. The assigned workbook label combines distinct credentials: this entry maps to the Canadian examination leading to Canadian Certified Genetic Counsellor (CCGC), while ABGC awards Certified Genetic Counselor (CGC®) through a separate examination. The assigned slug is preserved. No numerical unit weights are published in the consulted Canadian outline.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Epidemiology, Population, and Basic Human Geneticsnot stated
1.How does autosomal recessive segregation determine recurrence risk?
An autosomal recessive condition generally requires disease-causing variants in both copies of the relevant gene. When both parents are heterozygous carriers, each contributes either their usual allele or their disease-causing allele. The four equally likely combinations produce a one-quarter affected probability, one-half carrier probability and one-quarter non-carrier probability for each pregnancy. Previous outcomes do not change these probabilities when parental genotypes and the inheritance assumptions remain the same.
Apply it
Two confirmed carriers have three unaffected children and ask whether an affected pregnancy is now overdue. Explain that the next pregnancy still has a one-quarter affected probability; the earlier births do not compensate for future outcomes.
Common pitfall: Adding risks across pregnancies confuses an individual pregnancy probability with a family-level probability. Independent segregation does not create a predictable sequence of affected births.
2.How does reduced penetrance modify dominant inheritance counselling?
Penetrance is the proportion of people with a particular genotype who develop its associated phenotype. A heterozygous parent with an autosomal dominant variant usually has a one-half transmission probability, but transmission and clinical manifestation are separate events. Under an explicitly applicable penetrance estimate, the child's phenotype probability combines these events. An apparently unaffected relative therefore does not automatically exclude transmission through that branch, particularly when penetrance is incomplete or depends on age.
Apply it
A parent carries a dominant variant with a stipulated lifetime penetrance of 80%. Assuming the estimate applies to the child, calculate a 40% lifetime phenotype probability: one-half transmission multiplied by 80% penetrance.
Common pitfall: Reporting 80% as the child's risk ignores transmission. Reporting 50% as clinical certainty among offspring ignores incomplete penetrance and the estimate's population and age boundaries.
3.Which pedigree transmissions distinguish X-linked from autosomal inheritance?
A father transmits his X chromosome to daughters and his Y chromosome to sons. Consequently, direct father-to-son transmission of the same causal X-linked allele does not occur. A heterozygous mother can transmit an X-linked allele to children of either sex, with clinical effects depending on the condition and genotype. Pedigree interpretation should distinguish transmission rules from stereotyped severity: females can manifest X-linked disease, and small families may obscure an otherwise compatible pattern.
Apply it
A family attributes a father's and son's similar findings to direct transmission of one X-linked variant. Reconsider the model, verify both diagnoses and results, and explore another inheritance mechanism or independent causes before assigning recurrence risks.
Common pitfall: Treating every affected male pedigree as X-linked overlooks autosomal conditions. Shared phenotype alone does not prove that two relatives share the same causal variant.
4.Why can mitochondrial disease show maternal transmission and variable severity?
Mitochondrial DNA is ordinarily maternally inherited, whereas many proteins needed for mitochondrial function are encoded by nuclear genes. Heteroplasmy describes a mixture of mitochondrial DNA populations, and their proportions can differ among tissues and relatives. Clinical effects depend partly on the proportion and distribution of dysfunctional mitochondria. A mitochondrial phenotype therefore does not establish mitochondrial DNA inheritance, and a negative blood result may be less informative when the suspected variant is poorly represented in blood.
Apply it
Several maternal relatives have different combinations of hearing and muscle problems. A negative blood mitochondrial test does not settle the assessment; review the suspected mechanism, assay sensitivity and whether a more informative tissue is appropriate.
Common pitfall: Assuming all mitochondrial disorders follow maternal inheritance overlooks nuclear causes. Assuming blood represents every organ overlooks tissue-dependent heteroplasmy and changing variant proportions.
NHS Genomics Education — All about mitochondria: Definition and disease · NHS GeNotes — Mitochondrial DNA testing
5.How do imprinting and uniparental disomy alter ordinary inheritance expectations?
Genomic imprinting produces parent-of-origin differences in gene expression through epigenetic regulation. Uniparental disomy means that both copies of a chromosome or chromosome segment come from one parent. These mechanisms can disturb the expected balance of expressed parental alleles without a conventional coding sequence change. Isodisomy can also make a recessive variant homozygous. The discriminating question is whether the suspected disorder depends on sequence, dosage, parental origin or an imprinting mark.
Apply it
A laboratory excludes a coding variant in a suspected imprinting disorder. Explain why this result may leave the hypothesis unresolved and identify whether the clinical question instead requires assessment of methylation, dosage or parental origin.
Common pitfall: A normal sequence result does not establish normal imprinting. Conversely, uniparental disomy is not automatically pathogenic; consequences depend on the chromosome, region and alleles involved.
6.What distinguishes founder effect from natural selection?
A founder effect occurs when a new population begins with a small, unrepresentative sample of a larger population's genetic variation. Genetic drift then describes random allele-frequency changes, particularly influential in small populations. Neither mechanism requires an allele to improve survival or reproduction. Natural selection instead involves differences in reproductive contribution associated with heritable characteristics. A high local frequency can therefore reflect population history rather than a beneficial effect or a newly increased mutation rate.
Apply it
A rare recessive variant is common in a community descended from a few founders. Use population history to explain the frequency and consider an ancestry-relevant testing strategy without assuming every community member carries that variant.
Common pitfall: High frequency does not prove heterozygote advantage. Population membership changes a prior probability but cannot substitute for an individual's family history or laboratory result.
7.When can Hardy–Weinberg calculations estimate carrier frequency?
For a simplified two-allele autosomal model, Hardy–Weinberg genotype frequencies are p², 2pq and q², with p + q = 1. If a fully penetrant recessive condition has frequency q², the affected frequency can estimate q and then the heterozygote frequency 2pq. This requires an appropriate population model and reliable disease-frequency data. Population structure, consanguinity, selection, incomplete ascertainment and genetic heterogeneity can make a simple estimate unsuitable for an individual counselling decision.
Apply it
In a hypothetical equilibrium population, a recessive condition affects 1 in 10,000 people. Set q to 0.01 and p to 0.99; the carrier frequency is 0.0198, approximately 1 in 51 people.
Common pitfall: Using disease prevalence directly as carrier frequency omits the square-root step. Applying a pooled estimate to a founder subgroup may conceal substantial population differences.
8.How should study design change confidence in a genetic association?
An association between a variant and disease does not by itself establish causation or clinical usefulness. Assess how participants were selected, whether comparison groups differ in ancestry or relevant exposures, how outcomes were measured, and whether results replicate. Small samples can produce unstable estimates; biased sampling can produce precise but misleading estimates. Distinguish a statistically associated marker from a causal variant and distinguish either finding from evidence that testing improves decisions or outcomes.
Apply it
A small clinic study reports a strong variant association, but cases and controls come from different ancestral populations. Identify population structure as a competing explanation and seek appropriately matched replication before translating the finding into risk counselling.
Common pitfall: A small P value does not remove confounding or establish useful prediction. Increasing sample size reduces random error but does not automatically correct systematic selection bias.
CBGC — Exam Content Outline · ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
Clinical Geneticsnot stated
9.Why is an unaffected sibling's recessive carrier probability two-thirds?
For a fully penetrant childhood-onset autosomal recessive condition, two carrier parents produce four equally likely genotype combinations: one non-carrier, two carriers and one affected child. Once a sibling is known to be unaffected beyond the relevant onset period, the affected combination is excluded. Two of the three remaining combinations are carriers, giving a conditional probability of two-thirds. This result depends on the family model and on being able to exclude the affected genotype reliably.
Apply it
An unaffected adult has a sibling with a molecularly confirmed recessive condition, and both parents are carriers. Before testing, use two-thirds as the adult's carrier probability when the condition's onset and penetrance assumptions are satisfied.
Common pitfall: One-half is the unconditional carrier probability before considering unaffected status. Two-thirds is inappropriate when unaffected appearance cannot exclude disease because onset is later or penetrance incomplete.
NHS GeNotes — Visual communication aid: Autosomal recessive inheritance
10.How does a negative carrier test update a pedigree-based prior?
Bayesian updating combines the prior probability with the likelihood of the observed result under each possible state. For a negative carrier test, multiply the carrier prior by the false-negative probability and the non-carrier prior by the true-negative probability. Divide the carrier branch by the sum of both branches. A negative result reduces risk according to assay detection and specificity; it does not erase a strong prior when some relevant variants remain undetectable.
Apply it
With a carrier prior of one-half, 80% carrier detection and no false positives, the negative-result branches are 0.10 and 0.50. The posterior carrier probability is 0.10 divided by 0.60, or one-sixth.
Common pitfall: Multiplying the prior by the false-negative rate gives an unnormalised branch probability. It becomes a posterior probability only after division by all routes to the observed result.
CDC — Principles of Epidemiology, Lesson 5, Appendix A · CBGC — Exam Content Outline
11.Which findings establish a diagnostic route for Marfan syndrome, and why does recognition change care?
Marfan syndrome is an autosomal dominant connective-tissue disorder caused by FBN1 variants affecting fibrillin-1 and extracellular microfibrils. GeneReviews describes an explicit diagnostic route in a proband without a known family history: an FBN1 pathogenic variant known to be associated with Marfan syndrome together with either aortic-root enlargement with z score ≥2.0 or ectopia lentis establishes the diagnosis. Aortic measurements must account for age and body size; slit-lamp examination assesses ectopia lentis. Disproportionate limbs, pectus deformity and scoliosis support assessment but do not independently establish this route. Other pathways depend on family history and age. With a rigorously established family history, aortic-root dilatation meets the stated familial criterion at z score ≥2.0 from age 20, versus ≥3.0 below age 20; ectopia lentis or systemic score ≥7 provides another familial route. Care includes serial aortic imaging, appropriate beta-blocker or angiotensin-receptor-blocker therapy, ophthalmic care and preventive aortic surgery when indicated.
Apply it
An adult without a known family history has a Marfan-associated pathogenic FBN1 variant and an aortic-root z score of 2.3. This satisfies the stated molecular-plus-aortic route. Tall stature and an FBN1 VUS would not satisfy it. Establishing the diagnosis enables cardiovascular surveillance and assessment of relatives.
Common pitfall: Do not apply the route to every FBN1 finding: the variant must be pathogenic and associated with Marfan syndrome. Features can emerge with age, so a child below diagnostic thresholds may need follow-up. Pregnancy requires aortic-risk assessment and medication review; angiotensin receptor blockers are avoided during pregnancy.
FBN1-Related Marfan Syndrome - GeneReviews® - NCBI Bookshelf · CBGC — Exam Content Outline
12.What distinguishes variable expressivity from reduced penetrance?
Reduced penetrance concerns whether a genotype produces the associated phenotype at all. Variable expressivity concerns differences in the phenotype among people who manifest it, such as affected organs, severity or age at presentation. These features can coexist. A mildly affected parent may therefore have a more severely affected child without a change in the basic transmission probability. Describe which manifestations were assessed before deciding that a relative is unaffected rather than subtly affected.
Apply it
A parent and child share a pathogenic variant, but the parent has mild findings and the child has substantial disability. Explain variable expressivity and avoid promising that future children would resemble the parent's milder presentation.
Common pitfall: Calling every severity difference incomplete penetrance blurs presence with degree of expression. A familiar mild phenotype does not establish a reliable severity prediction for another relative.
NHS Genomics Education — Do our genes govern our fate? · NHS GeNotes — Penetrance
13.How does consanguinity increase recessive disease risk?
Biologically related partners are more likely than unrelated partners to share alleles inherited from a common ancestor. Their child consequently has an increased probability of inheriting two copies that are identical by descent. The inbreeding coefficient describes that probability at a locus, rather than the probability of any genetic disorder. For the child of first cousins with otherwise unrelated ancestors, the conventional coefficient is one-sixteenth. Actual clinical risk also depends on the family's variants and background population.
Apply it
First-cousin partners ask whether one-sixteenth means their child has a 6.25% chance of a named disease. Explain the coefficient's meaning, document the pedigree and assess condition-specific carrier risks separately from the relatedness measure.
Common pitfall: The inbreeding coefficient is not a universal disease probability. Assuming relatedness makes every recessive condition equally likely ignores allele frequencies and the actual family history.
CBGC — Exam Content Outline · NHS GeNotes — Autosomal recessive inheritance
14.How do syndrome, sequence and association guide phenotype interpretation?
A syndrome groups findings linked by an underlying cause, while a sequence describes multiple consequences arising from one initiating developmental event. An association is a non-random grouping of findings without an established single causal explanation. These distinctions change how observations are counted and interpreted: several consequences of one developmental disturbance need not represent independent abnormalities. A phenotype assessment should describe findings precisely, establish their developmental relationships and then select investigations that address the plausible mechanisms.
Apply it
A fetus has several abnormalities plausibly downstream of one mechanical constraint. Consider whether a sequence explains the pattern before treating each finding as independent evidence for a multisystem syndrome or choosing a narrowly targeted molecular test.
Common pitfall: A recognisable cluster is not automatically a syndrome with one known gene. Descriptive classification helps construct a differential but does not itself establish etiology.
15.Why can a balanced rearrangement matter in recurrent pregnancy loss?
A balanced chromosome rearrangement can preserve the carrier's overall genetic dosage while changing chromosome structure. During meiosis, segregation may produce gametes with unbalanced chromosome material, creating risks of pregnancy loss or an affected pregnancy. This is one possible explanation within a broader recurrent-loss assessment, rather than an explanation for every family. When the specific question concerns balanced chromosome structure, karyotyping can be informative even when a copy-number microarray shows no imbalance in the parent.
Apply it
A couple with recurrent losses has a normal parental microarray result and asks whether a balanced translocation was excluded. Explain the assay boundary and consider chromosome analysis if the clinical assessment supports investigating a structural rearrangement.
Common pitfall: A normal dosage result does not exclude a balanced rearrangement. Finding a rearrangement also does not justify assigning a universal recurrence percentage without its specific details.
16.How is inherited hypertrophic cardiomyopathy distinguished from other causes of ventricular thickening?
Hypertrophic cardiomyopathy involves otherwise unexplained left-ventricular hypertrophy; an adult wall thickness of at least 15 mm is a usual diagnostic threshold, with context-dependent lower thresholds in affected families. Hypertension, valve disease, athletic adaptation and storage disorders require consideration. Sarcomeric causes, commonly involving MYBPC3 or MYH7, usually show autosomal dominant inheritance with age-dependent penetrance. Evaluate with ECG, echocardiography, family history, selected cardiac MRI and appropriate genetic testing. Management addresses symptoms and obstruction, monitors arrhythmias and assesses sudden-death risk to determine whether an implantable defibrillator is indicated. [GeneReviews: hypertrophic cardiomyopathy](https://www.ncbi.nlm.nih.gov/sites/books/NBK1768/).
Apply it
An adult with unexplained septal hypertrophy and a young relative who died suddenly warrants inherited-cardiac assessment. A familial pathogenic variant enables targeted testing; young carriers with normal imaging still need age-appropriate surveillance.
Common pitfall: Ventricular thickening does not automatically establish sarcomeric disease. A negative panel does not exclude clinical HCM, and a normal examination in a young relative does not exclude later expression.
Molecular Geneticsnot stated
17.When does a coding insertion or deletion cause a frameshift?
Coding sequence is read in groups of three nucleotides. An insertion or deletion whose size is not divisible by three generally changes the downstream reading frame, altering subsequent codons and potentially introducing a premature stop. A three-nucleotide deletion can preserve the frame while removing an amino acid. Neither label alone establishes pathogenicity: transcript context, position, biological mechanism and supporting evidence determine whether the change disrupts function in a clinically relevant way.
Apply it
A report lists a two-base deletion within a coding exon. Predict a frameshift, then examine the affected transcript and disease mechanism rather than concluding that any frameshift in any gene necessarily explains the patient's phenotype.
Common pitfall: Calling every deletion a frameshift ignores deletions divisible by three. Conversely, preserving the reading frame does not guarantee that the altered protein remains functional.
NHGRI — Frameshift Mutation · ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
18.How do CFTR dysfunction, diagnostic testing and treatment connect in cystic fibrosis?
Cystic fibrosis is an autosomal recessive disorder caused by biallelic CF-causing CFTR variants that impair epithelial chloride and bicarbonate transport. Recurrent respiratory infection or bronchiectasis together with pancreatic insufficiency, poor growth or meconium ileus are informative clues. Diagnosis requires a compatible presentation, positive newborn screen or family history plus evidence of CFTR dysfunction, such as sweat chloride at least 60 mmol/L or biallelic CF-causing variants. Molecular testing may require sequencing and deletion–duplication analysis. Care includes airway clearance, infection treatment and pancreatic enzymes when insufficient; CFTR modulators require a responsive genotype. [GeneReviews: cystic fibrosis](https://www.ncbi.nlm.nih.gov/sites/books/NBK1250/).
Apply it
An infant with a positive newborn screen, poor weight gain and greasy stools needs diagnostic assessment and evaluation for pancreatic insufficiency. A limited negative variant panel cannot exclude CF when the biochemical and clinical findings remain compelling.
Common pitfall: Two CFTR findings must be interpreted for disease causation and phase; two VUS do not establish CF. CFTR-related disease can be milder or organ-limited, and modulator eligibility cannot be inferred merely from the gene name.
NHS GeNotes — Autosomal recessive inheritance · ACMG/AMP — Standards and guidelines for the interpretation of sequence variants · CBGC — Exam Content Outline
19.How are sequence-variant evidence strengths combined into a classification?
The foundational ACMG/AMP framework uses pathogenic, likely pathogenic, uncertain significance, likely benign and benign categories. Pathogenic evidence strengths include very strong, strong, moderate and supporting; combinations, rather than an unweighted count, determine classification. Under the original rules, two independent strong pathogenic criteria meet a pathogenic combination. For example, a well-established functional assay satisfying PS3 at strong strength plus an independent, appropriately controlled case–control association satisfying PS4 at strong strength yields pathogenic when there is no conflicting evidence. By contrast, one moderate criterion plus one supporting criterion does not meet an original likely pathogenic combination and remains uncertain on those stipulated findings. Apply relevant [ClinGen variant-classification refinements](https://www.clinicalgenome.org/tools/clingen-variant-classification-guidance/), including PVS1, functional, computational and gene-specific specifications, alongside the foundational framework.
Apply it
Suppose independent functional and case–control studies have already been evaluated and legitimately assigned PS3_Strong and PS4_Strong, with no contrary evidence. Combine two strong criteria to classify the variant as pathogenic under the original framework. If the only valid evidence is PM1_Moderate and PP3_Supporting, the stipulated combination remains a VUS. Neither example permits adding correlated observations as extra criteria.
Common pitfall: A predicted loss-of-function change does not automatically qualify for PVS1 at very strong strength. Loss of function must be an established disease mechanism, and the relevant transcript, exon usage, predicted nonsense-mediated decay and possibility of retaining function affect applicability and strength. Computational strength also depends on validated calibration; several correlated predictions are not independent criteria.
ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
20.How should a variant of uncertain significance affect management?
A variant of uncertain significance lacks sufficient evidence for either a disease-causing or benign classification. It should not independently determine clinical management or be treated as a confirmed familial explanation. Decisions can still be supported by the person's phenotype, family history and other established findings. Useful follow-up focuses on evidence that could change classification, such as informative segregation or validated functional data, alongside a clear plan for communicating clinically relevant reinterpretation.
Apply it
A client considers irreversible preventive surgery after receiving a VUS result. Explain the uncertainty, distinguish the VUS from a pathogenic result and assess management using established personal and family risk information rather than the uncertain variant alone.
Common pitfall: Calling a VUS almost positive encourages unsupported intervention. Calling it harmless is equally inaccurate because uncertainty can resolve in either direction as evidence develops.
ACMG/AMP — Standards and guidelines for the interpretation of sequence variants · NHS GeNotes — Visual communication aid: Variants of uncertain significance
21.When can family segregation clarify a variant's significance?
Segregation examines whether a variant tracks with disease in relatives under the proposed inheritance model. Its strength depends on informative relationships, reliable phenotyping, penetrance, age and possible alternative causes. A variant's presence in several affected relatives can support interpretation, but shared inheritance of nearby variation can complicate causal inference. An apparently unaffected carrier is not automatically decisive benign evidence in a late-onset or incompletely penetrant disorder. Family testing should answer a specific interpretive question.
Apply it
A laboratory requests samples from two clearly affected relatives to evaluate a VUS. Explain that this is an evidence-gathering segregation study, with possible reclassification value, rather than predictive testing that already establishes their disease status.
Common pitfall: Testing many uninformative relatives does not automatically strengthen classification. Failure to account for age, phenocopies or incomplete penetrance can make segregation appear more decisive than it is.
ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
22.How do assay capabilities limit a negative molecular result?
A negative molecular result excludes only changes that the performed assay can detect reliably in the analysed material. Sequencing, deletion–duplication analysis and chromosome methods answer overlapping but different questions. Interpretation should consider genes assessed, coverage, variant classes, mosaic detection and whether the relevant biological mechanism was tested. Expanding the number of genes does not necessarily improve detection of every type of change. A residual-risk explanation should identify the specific unresolved mechanism rather than simply saying testing is imperfect.
Apply it
A negative panel report states that exon-level copy-number changes were not assessed. If the phenotype remains compelling, review whether deletion–duplication testing would address that gap before interpreting the result as excluding the suspected condition.
Common pitfall: A broad panel is not automatically comprehensive for every variant class. A normal sequence result cannot be assumed to exclude dosage changes or balanced chromosome rearrangements.
NCI — Genetic Testing for Inherited Cancer Risk · NHS GeNotes — Microarray · NHS GeNotes — Karyotype
23.Why does phase matter when two recessive variants are found?
Two different variants in the same gene are compound heterozygous when they occupy opposite copies, or are in trans. If both lie on one copy, or in cis, the other copy may remain unaffected by those variants. For a recessive diagnosis, counting two findings is therefore insufficient: their classification, phase and fit with the phenotype all matter. Parental testing can help establish phase when each parent contributes a different variant, although family circumstances and assay details affect interpretation.
Apply it
A child has two pathogenic variants in a recessive gene. Testing shows both were inherited together from one parent. Reassess whether the other gene copy contains a relevant undetected change rather than assuming biallelic disease is established.
Common pitfall: Two report entries do not necessarily mean two affected alleles. Phase cannot rescue variants whose classifications or relationship to the clinical presentation remain unsupported.
NHS GeNotes — Autosomal recessive inheritance · ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
Cytogeneticsnot stated
24.Which chromosome question favours karyotyping over microarray?
Karyotyping examines chromosome number and visible chromosome structure, allowing detection of sufficiently large balanced rearrangements. Microarray assesses genomic copy number at higher resolution for deletions and duplications, but generally does not identify a balanced exchange with no net dosage change. Test choice should follow the suspected abnormality rather than a simple ranking of newer versus older technology. A normal microarray and a normal karyotype therefore exclude different sets of possible explanations.
Apply it
An unaffected adult's family history suggests a balanced reciprocal translocation. Choose an investigation capable of showing chromosome structure rather than assuming that a high-resolution dosage assay will answer the same structural question.
Common pitfall: Higher resolution for copy number does not imply better detection of every chromosome change. Conversely, a normal karyotype does not exclude small pathogenic deletions.
25.How do SNP arrays differ from array comparative genomic hybridisation?
Both SNP-based arrays and array comparative genomic hybridisation can assess copy-number imbalance, but SNP arrays additionally provide genotype information. This can reveal regions of homozygosity that a dosage-only comparison may not identify. Such regions can prompt questions about parental relatedness, uniparental inheritance or recessive disease, depending on their distribution and context. A region of homozygosity is a clue, not independent proof of a specific mechanism, and interpretation must respect the capabilities of the actual platform.
Apply it
A report shows normal copy number but a long homozygous region on one chromosome. Recognise the value of SNP information and consider what parental or targeted testing could distinguish possible explanations for the pattern.
Common pitfall: Treating all microarrays as interchangeable obscures platform-specific information. A homozygous region alone does not establish uniparental disomy or prove that it explains the phenotype.
26.Which combination suggests 22q11.2 deletion syndrome, and what follows confirmation?
A conotruncal heart defect, palatal dysfunction, hypocalcaemia and immune deficiency form an informative pattern for 22q11.2 deletion syndrome, although expression varies widely. The mechanism is a heterozygous contiguous-gene deletion, usually de novo for the common deletion but transmissible in an autosomal dominant pattern. Chromosomal microarray can establish the deletion; a routine karyotype may miss it. Following diagnosis, evaluate cardiac anatomy, calcium, immune function, hearing and development. Treat identified cardiac and calcium problems, provide developmental support and assess immune status before live vaccines. [GeneReviews: 22q11.2 deletion syndrome](https://www.ncbi.nlm.nih.gov/sites/books/NBK1523/).
Apply it
An infant with tetralogy of Fallot and hypocalcaemic seizures needs both immediate treatment of the calcium disturbance and investigation for a unifying deletion syndrome. Test parents for the child's deletion to clarify familial transmission and reproductive risk.
Common pitfall: An absent family history or mild parental phenotype does not exclude an inherited deletion. A carrier has a one-half transmission probability, but the child's severity cannot be predicted from the parent's presentation.
CBGC — Exam Content Outline · NHS GeNotes — Microarray · NHS GeNotes — Karyotype
27.How does mosaicism change the meaning of a laboratory result?
Mosaicism is the presence of genetically different cell populations derived from one fertilised egg. A postzygotic change can affect only some tissues or proportions of cells. The measured proportion therefore depends on the sampled tissue and the assay's sensitivity, and it need not equal the proportion in a clinically affected organ or the germline. A negative blood result can leave tissue-limited mosaicism unresolved, while a positive result requires interpretation in relation to phenotype and sampling.
Apply it
A patient has strongly segmental findings but an unremarkable blood result. Consider whether the suspected change could be confined to affected tissue and discuss a specimen and assay that can meaningfully assess that possibility.
Common pitfall: A blood mosaic percentage is not a whole-body percentage or a direct reproductive risk. Failure to detect a variant in one tissue does not exclude every mosaic distribution.
28.Why does the chromosome mechanism matter after recognising Down syndrome?
Down syndrome results from extra chromosome 21 material. Neonatal hypotonia, characteristic facial findings and an atrioventricular septal defect can suggest it, but chromosome testing confirms the diagnosis. Most cases involve free trisomy from meiotic mis-segregation; others involve a translocation or mosaicism. Karyotyping distinguishes these mechanisms and directs recurrence assessment. When a translocation is found, parental karyotypes can identify a balanced carrier. Care includes assessment for congenital heart disease, feeding difficulties, hearing and thyroid problems, together with developmental support. [NHS: Down syndrome](https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/down-syndrome-trisomy-21/) and [Safer Care Victoria neonatal guidance](https://www.safercare.vic.gov.au/best-practice-improvement/clinical-guidance/neonatal/down-syndrome).
Apply it
After confirming extra chromosome 21 material in an infant, establish whether the result represents free trisomy, a translocation or mosaicism. A translocation changes the family investigations needed; the diagnosis also triggers assessment of associated health needs.
Common pitfall: A positive prenatal screen is not a chromosome diagnosis. Neither appearance nor a blood mosaic percentage precisely predicts development, and recurrence counselling must not assume that every case has the same chromosome mechanism.
NHS GeNotes — Karyotype · NHS GeNotes — Mosaicism · CBGC — Exam Content Outline
29.How are numerical abnormalities and structural rearrangements decoded in chromosome notation?
In 47,XY,+21, 47 is the total chromosome count, XY is the sex-chromosome complement and +21 denotes an additional chromosome 21. In the illustrative result 46,XX,t(2;8)(q21;p23), 46 is the count, XX is the sex-chromosome complement and t denotes a translocation involving chromosomes 2 and 8. The ordered breakpoints are chromosome 2 long arm, region 2 band 1, and chromosome 8 short arm, region 2 band 3. This describes an apparently balanced reciprocal translocation at karyotype resolution; it does not establish that every breakpoint preserves gene function.
Apply it
Decode count, sex chromosomes and abnormality separately before discussing consequences. A numerical result does not predict individual severity; an apparently balanced structural result may require additional investigation for cryptic imbalance or gene disruption when the phenotype warrants it.
Common pitfall: Separately, 1qh+ denotes increased constitutive heterochromatin on chromosome 1's long arm and is a recognised heteromorphism without phenotypic consequence. Do not equate it with a pathogenic euchromatic duplication or use it to explain unrelated developmental findings.
Biochemical Geneticsnot stated
30.How does an enzyme block disturb a metabolic pathway?
Enzymes catalyse particular chemical reactions. If an enzyme's activity is reduced, its substrate may accumulate while formation of its product declines; alternative pathways may also change the resulting metabolite pattern. The clinical effect depends on the pathway, residual activity and the consequences of substrate excess or product deficiency. Reasoning from a defined pathway helps distinguish a direct biochemical consequence from an unrelated abnormal result and identifies which measurements could test the proposed block.
Apply it
In a stipulated pathway A becomes B through enzyme X, then B becomes C through enzyme Y. Low Y activity with preserved X predicts B accumulation and reduced C production, making those metabolites informative measurements.
Common pitfall: Assuming every metabolite rises after an enzyme defect ignores position in the pathway. Accumulated substrate and deficient downstream product can contribute differently to disease.
31.Which biochemical question is answered by an enzyme assay?
An enzyme assay measures catalytic activity in a specified sample, whereas metabolite testing measures concentrations or patterns resulting from pathway activity. These approaches answer related but distinct questions. A result must be interpreted against the specimen, reference interval, analytical method and clinical setting. A molecular finding proposes a genetic explanation; functional and metabolite observations can examine its biochemical consequences. Agreement among phenotype, biochemical pattern and molecular mechanism is more informative than treating any abnormal number as independently diagnostic.
Apply it
A report describes low conversion of a defined substrate in a validated assay. Interpret this as evidence about enzyme activity, then compare it with the predicted metabolite pattern and clinical findings rather than calling it a direct DNA measurement.
Common pitfall: An enzyme assay is not sequencing, and a metabolite concentration is not a direct activity measurement. Discordant findings require investigation rather than automatic selection of one result.
32.How does PAH deficiency cause PKU, and why does early treatment help?
PAH-related phenylketonuria is autosomal recessive. Biallelic disease-causing PAH variants reduce phenylalanine hydroxylase activity, impairing conversion of phenylalanine to tyrosine; the reaction normally uses tetrahydrobiopterin as a cofactor. Phenylalanine accumulates and can injure the developing brain before obvious symptoms. Prescribed phenylalanine restriction reduces substrate entering the blocked pathway, while appropriate medical nutrition and supplementation maintain adequate protein equivalents, tyrosine and other nutrients. Treatment is adjusted using blood phenylalanine and nutritional monitoring. Ontario screening measures phenylalanine; an elevated screening marker requires diagnostic follow-up rather than proving PAH deficiency by itself.
Apply it
A well newborn with elevated screening phenylalanine needs prompt confirmatory biochemical assessment and investigation of the cause. If PAH deficiency is established, early dietary treatment can prevent harm that would otherwise precede recognition through developmental symptoms.
Common pitfall: Phenylalanine is essential, so treatment is controlled restriction rather than complete elimination or unsupervised protein avoidance. A positive screening marker does not establish the causal genotype or replace diagnostic confirmation.
PAH gene: MedlinePlus Genetics · Phenylketonuria: MedlinePlus Genetics · Newborn Screening Ontario — Phenylketonuria
33.How does biochemical monitoring complement a genetic diagnosis in PKU?
A genetic diagnosis identifies an underlying cause, but it does not continuously measure the current biochemical state. In phenylketonuria, monitoring phenylalanine provides information about ongoing metabolic control and response to management. Dietary phenylalanine intake and prescribed medical nutrition are adjusted to control accumulation while supporting growth and nutritional adequacy. The stable presence of causal variants therefore does not make repeat biochemical measurement redundant. Molecular testing concerns etiology and inheritance, while serial metabolite measurements help evaluate whether present management is achieving its biochemical aims.
Apply it
A family asks why blood monitoring continues after molecular confirmation of PKU. Explain that the causal genotype remains the same while phenylalanine levels can change, so monitoring informs current dietary and treatment adjustments rather than repeatedly proving inheritance.
Common pitfall: A confirmed genotype does not establish that biochemical control is currently adequate. A single favourable metabolite result also does not show that future monitoring is unnecessary.
Newborn Screening Ontario — Phenylketonuria · Phenylketonuria: MedlinePlus Genetics · PAH gene: MedlinePlus Genetics
34.Why does a metabolic phenotype not establish one inheritance pattern?
Metabolic dysfunction describes a physiological problem rather than a single inheritance mechanism. Some disorders involve nuclear genes, while others involve mitochondrial DNA; the resulting recurrence framework differs. Even mitochondrial function depends on proteins encoded in both genomes. A biochemical pathway result may narrow the functional defect without identifying its genetic origin. Integrate enzyme or metabolite results with molecular evidence and family history before applying recessive, dominant, X-linked or mitochondrial transmission assumptions to relatives.
Apply it
A patient has biochemical evidence of mitochondrial dysfunction and asks whether only maternal relatives are at risk. Clarify that a nuclear cause remains possible and establish the molecular mechanism before assigning a maternal transmission pattern.
Common pitfall: The words metabolic and mitochondrial are not inheritance diagnoses. Applying maternal inheritance to every mitochondrial phenotype can exclude relevant paternal or recessive family risks.
NHS Genomics Education — All about mitochondria: Definition and disease
Cancer Geneticsnot stated
35.Which findings suggest BRCA1/BRCA2-associated susceptibility, and how does confirmation change care?
Young-onset breast cancer, ovarian cancer, male breast cancer and relevant pancreatic or prostate cancers can suggest BRCA1/BRCA2-associated susceptibility. Both parental lineages matter. BRCA proteins repair damaged DNA; a germline pathogenic variant confers autosomal dominant susceptibility, with additional somatic events contributing to tumour development. Germline testing should assess sequence variants and relevant deletions or duplications. Confirmation enables targeted family testing and discussions of earlier breast surveillance with MRI and mammography, risk-reducing mastectomy and risk-reducing salpingo-oophorectomy according to gene, age and reproductive plans. [NCI: BRCA gene changes](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet).
Apply it
A family includes young-onset breast cancer and ovarian cancer on the paternal side. Verify diagnoses and prioritise an informative affected relative for testing. A pathogenic result can change prevention discussions for relatives who inherit it.
Common pitfall: Paternal transmission does not weaken a BRCA hypothesis. A VUS is not a basis for syndrome-specific preventive surgery, and ovarian ultrasound or CA-125 screening has not been shown to provide an effective substitute for risk-reducing surgery.
NCI — Cancer Genetics Risk Assessment and Counseling (PDQ) · NCI — Genetic Testing for Inherited Cancer Risk
36.Why is an affected relative often the most informative first cancer test?
Testing a relative whose cancer strongly fits the suspected familial syndrome gives the best opportunity to identify an explanatory germline variant. Once a pathogenic familial variant is established, relatives can receive targeted testing with a clearer interpretation. Starting with an unaffected relative can yield a negative result that leaves the family cause unresolved. The best initial person depends on the diagnoses, ages, availability and suspected syndrome, rather than simply choosing whoever first attends counselling.
Apply it
An unaffected client attends with a sister who developed a relevant cancer unusually young. Discuss whether the sister's testing would first establish an informative familial target, while respecting each person's independent consent and access circumstances.
Common pitfall: Testing the easiest available person is not always the most informative strategy. An unaffected person's negative broad test cannot automatically substitute for identifying the family's cause.
37.How does tumour testing differ from germline testing?
Tumour testing examines changes present in cancer tissue and may identify variants acquired during tumour development. Germline testing asks whether a variant is constitutionally present and potentially relevant to inherited susceptibility. A tumour finding can raise a germline question but does not alone establish that relatives carry the same variant. The specimen and purpose of testing are therefore decisive. A clinically relevant tumour result may guide treatment while requiring separate assessment before conclusions about familial transmission are drawn.
Apply it
A client receives a tumour report naming a cancer-susceptibility gene and assumes each child has a one-half risk. Explain that inherited transmission depends on establishing germline status, rather than the gene name appearing in tumour tissue.
Common pitfall: A familiar hereditary gene can acquire a somatic variant in a tumour. Conversely, calling a result a tumour finding does not prove that germline involvement is absent.
38.When is a negative cancer result a true negative?
A true negative can be established when a known disease-causing familial variant is specifically assessed and is absent in the relative tested. It answers whether that person inherited that particular susceptibility variant. The result does not imply immunity from cancer or necessarily remove risks arising from another lineage, personal factors or a different condition. Its informativeness depends on the familial variant being a valid explanation and the test adequately assessing the relevant change.
Apply it
A client tests negative for a confirmed pathogenic variant found in an affected parent. Explain that this excludes inheritance of that familial variant, then assess other personal and family factors before describing the client's overall cancer risk.
Common pitfall: True negative refers to a defined familial target, not universal cancer protection. The term should not be applied when no causative familial variant has been established.
39.Why can a negative cancer panel remain uninformative?
When no explanatory familial variant is known, a negative panel may leave several possibilities: the family has no detectable inherited cause, the causal gene was not assessed, or the relevant change was beyond the assay's capabilities. The result therefore does not automatically erase a concerning pedigree. Risk assessment continues to use personal and family history. The key distinction is between excluding a specified familial variant and failing to discover an explanation in the person tested.
Apply it
An unaffected person with several young affected relatives receives a negative panel. Explain why this result may remain uninformative and review whether testing an affected relative or reassessing assay coverage could provide more useful evidence.
Common pitfall: Negative is a laboratory result, not a complete risk conclusion. Reassurance appropriate after a targeted true negative may be inappropriate when the family's genetic explanation remains unknown.
NCI — Genetic Testing for Inherited Cancer Risk · NCI — Cancer Genetics Risk Assessment and Counseling (PDQ)
40.How does cascade testing turn one result into family-specific risk assessment?
Cascade testing offers relatives testing for an established familial pathogenic variant, moving through biologically relevant family branches. The known target makes results more interpretable than an unexplained broad-panel negative. Counselling should explain who may share the variant, how transmission occurs and what a positive or negative result would mean for that person. Family communication is important, but each relative retains a separate decision about testing and the original client's confidentiality remains relevant.
Apply it
A pathogenic variant is confirmed in a client. Help the client prepare accurate information for relatives, identify the appropriate familial test and explain how results could clarify their own risk without assuming that every relative wants testing.
Common pitfall: A VUS is not an established pathogenic target for routine predictive cascade testing. Familial relevance also does not create automatic permission to disclose the client's report.
NCI — Cancer Genetics Risk Assessment and Counseling (PDQ) · Core Competencies for Genetic Counsellors in Canada 2025
41.How do recognition, tumour investigation and gene-specific surveillance connect in Lynch syndrome?
Colorectal and endometrial cancers, particularly early diagnoses or multiple affected relatives, suggest Lynch syndrome; an unremarkable family history does not exclude it. Susceptibility is usually autosomal dominant through pathogenic MLH1, MSH2, MSH6 or PMS2 variants, or an EPCAM deletion that silences MSH2. Deficient mismatch repair produces microsatellite instability. Tumour immunohistochemistry or microsatellite-instability testing guides investigation, while germline assessment establishes inherited susceptibility. As a dated example, NCI's gene-specific table reports NCCN 2024 colonoscopy recommendations: MLH1/MSH2 carriers start at 20–25 years and repeat every 1–2 years; MSH6/PMS2 carriers start at 30–35 years and repeat every 1–3 years. EPCAM follows MSH2. Earlier family colorectal diagnoses can advance initiation: 2–5 years before the earliest diagnosis when it occurred before 25 for MLH1/MSH2 or before 30 for MSH6/PMS2. Counselling also addresses endometrial and other associated risks.
Apply it
A colorectal tumour lacks MLH1 and PMS2 expression. Investigate MLH1 promoter methylation through the relevant tumour pathway before attributing the pattern to inherited Lynch syndrome. For a confirmed 32-year-old MSH6 carrier without an earlier family diagnosis, the cited NCCN 2024 example places colonoscopy initiation within the 30–35-year range, with a 1–3-year interval.
Common pitfall: Tumour mismatch-repair deficiency does not itself establish a germline diagnosis, and Lynch syndrome does not require hundreds of polyps. Surveillance recommendations differ among guidelines and change over time; the attributed NCCN 2024 example is not an official CBGC management rule.
Genetics of Colorectal Cancer (PDQ®) - NCI · NCI — Genetic Testing for Inherited Cancer Risk
Genetic Screeningnot stated
42.How do sensitivity and specificity use different denominators?
Sensitivity is the proportion of affected people who test positive: true positives divided by true positives plus false negatives. Specificity is the proportion of unaffected people who test negative: true negatives divided by true negatives plus false positives. Both begin with known disease status, whereas predictive values begin with the test result. Writing the denominator explicitly prevents confusion between detecting disease and estimating what a particular positive or negative result means for a screened individual.
Apply it
A validation sample includes 80 affected people, of whom 72 test positive, and 920 unaffected people, of whom 874 test negative. Calculate sensitivity as 72/80, or 90%, and specificity as 874/920, or 95%.
Common pitfall: Dividing true positives by all positive results calculates positive predictive value, not sensitivity. A high specificity does not mean that every positive result is diagnostic.
43.Why does positive predictive value change with prevalence?
Positive predictive value is the proportion of positive results that are true positives. With sensitivity and specificity held constant, a lower prevalence reduces the number of true positives relative to false positives generated among the much larger unaffected group. A highly specific test can therefore have a modest positive predictive value in a low-prevalence population. Counselling should use the relevant screened population or individual prior risk, rather than translating sensitivity directly into the probability that a positive result is correct.
Apply it
In 10,000 people with 1% prevalence, 90% sensitivity and 99% specificity produce 90 true positives and 99 false positives. Positive predictive value is 90/189, approximately 47.6%, despite the high specificity.
Common pitfall: Sensitivity answers how often disease is detected, not whether a positive result is true. Ignoring prevalence can substantially exaggerate certainty after population screening.
44.How should a negative screen be translated into residual risk?
A negative screen lowers risk according to test performance and the probability of disease before testing. False negatives remain possible, so a negative result cannot universally exclude the condition or override strong clinical findings. Negative predictive value is true negatives divided by all negative results, and it depends on prevalence as well as sensitivity and specificity. The transferable question is whether the result adequately addresses the current clinical concern, not simply whether its label is reassuring.
Apply it
A child develops suggestive clinical findings after a negative newborn screen. Explain that the earlier screen did not test every disorder or identify every affected infant, and support diagnostic assessment of the present findings.
Common pitfall: A screen-negative result is not a lifetime guarantee of health. Applying a population negative predictive value to a highly selected symptomatic person can misrepresent residual risk.
CDC — Principles of Epidemiology, Lesson 5, Appendix A · Newborn Screening Ontario — Screen Positive Results
45.What does a screen-positive newborn result require?
A screen-positive result identifies a baby who needs further assessment because the screening pattern suggests increased risk. It is not equivalent to a confirmed diagnosis. The follow-up pathway may include clinical review and additional biochemical or genetic testing, selected for the suspected condition. Communication must preserve both ideas: many positive screens need clarification, and timely follow-up matters because some screened conditions benefit from intervention before an infant becomes visibly unwell or experiences preventable harm.
Apply it
Parents interpret a screening telephone call as certainty that their baby is affected. Explain the distinction, describe the purpose of the arranged follow-up tests and help them understand why prompt assessment is still appropriate for a well baby.
Common pitfall: Calling the result diagnostic creates unnecessary certainty. Calling it probably nothing can undermine timely follow-up and obscure the reason the screening programme contacted the family.
46.Which features make a screening programme clinically useful?
A screening programme needs more than an analytically accurate test. It must define its target population, establish a meaningful condition or risk state to detect, and provide an effective route from a positive result to confirmation and beneficial action. Benefits must be considered alongside false results, anxiety, uncertain findings, access barriers and consent. Newborn PKU screening illustrates the connection between early detection, confirmatory assessment and management that can prevent harm before clinical deterioration.
Apply it
A proposed screen has excellent laboratory performance but no accessible confirmatory service. Identify the missing care pathway and ask how a positive result would lead to a verified diagnosis and useful action for the screened person.
Common pitfall: Analytical performance alone does not establish programme benefit. Detecting more findings can increase uncertainty or inequity if confirmation, counselling and effective follow-up are unavailable.
Newborn Screening Ontario — Screen Positive Results · Newborn Screening Ontario — Phenylketonuria · Core Competencies for Genetic Counsellors in Canada 2025
Prenatal Diagnosisnot stated
47.Why is non-invasive prenatal testing a screen rather than a diagnosis?
Non-invasive prenatal testing analyses cell-free DNA in maternal blood, including DNA originating largely from the placenta. It estimates risk for the conditions included in the test rather than directly establishing the chromosome constitution of every fetal cell. Placental and fetal findings can differ, and false-positive and false-negative results remain possible. A high-chance result should therefore lead to counselling about its condition-specific meaning and diagnostic options before decisions are based on an assumed confirmed fetal diagnosis.
Apply it
A pregnant client receives a high-chance result and asks whether the fetus is definitely affected. Explain the placental source, interpret the result as increased probability and discuss diagnostic testing that can address the chromosome finding.
Common pitfall: Highly accurate screening is still not diagnostic certainty. Calling the analysed DNA purely fetal overlooks placental biology and an important reason that discordant results occur.
48.How do CVS and amniocentesis compare in timing, specimen and pregnancy-loss risk?
Prenatal Screening Ontario describes CVS at approximately 11–14 weeks and amniocentesis after approximately 15 weeks. CVS obtains placental tissue and permits earlier testing and results; amniocentesis obtains amniotic fluid containing fetal genetic material later in pregnancy. The different source matters when placental mosaicism raises uncertainty about fetal involvement. Ontario's patient information describes an additional miscarriage risk of less than 1% for either procedure. This broad procedure-attributable estimate is separate from baseline pregnancy loss and does not establish identical risks for every patient or centre. Either procedure supplies material; the ordered chromosome or molecular analyses define what is assessed.
Apply it
Compare the value of earlier information from CVS with later amniotic-fluid sampling, the suspected condition, possible placental–fetal discordance and the centre's procedure-specific estimate. For a known familial sequence variant, arrange its targeted analysis rather than assuming that chromosome testing includes it.
Common pitfall: Do not present less than 1% as total pregnancy-loss risk or compare raw post-procedure loss rates without accounting for baseline differences. A specimen collection procedure is not an automatic assessment of every genetic condition.
Prenatal Screening Ontario — Chorionic Villus Sampling · Prenatal Screening Ontario — Amniocentesis
49.Why does maternal PKU require management even when the fetus is not expected to have PKU?
High maternal phenylalanine can harm fetal development through prenatal exposure, independently of whether the fetus has biallelic PAH variants. Poorly controlled maternal PKU is associated with intellectual disability, microcephaly, impaired growth and congenital heart defects in offspring, as well as increased pregnancy-loss risk. Reproductive counselling must therefore address two separate questions: the child's inherited PAH-related risk and the pregnancy's exposure to elevated maternal phenylalanine. Preconception metabolic assessment and prescribed phenylalanine control, continued during pregnancy with biochemical and nutritional monitoring, address the exposure mechanism.
Apply it
A person with PKU planning pregnancy has a partner established not to carry a relevant PAH variant. Under that stipulated genetic model, their children would be carriers rather than affected with PKU. This does not remove maternal phenylalanine toxicity: arrange metabolic and obstetric planning before conception rather than relying on the child's predicted genotype.
Common pitfall: A reassuring fetal inheritance calculation does not measure maternal metabolic control. Complete phenylalanine elimination or unsupervised protein restriction is inappropriate because phenylalanine is essential and pregnancy requires adequate nutrition.
Phenylketonuria: MedlinePlus Genetics · PAH gene: MedlinePlus Genetics
50.How can confined placental mosaicism explain discordant prenatal results?
Confined placental mosaicism describes a chromosome difference present in placental cells that is not necessarily present in the fetus. Because cell-free DNA screening and CVS both obtain information related to the placenta, agreement between them may not always resolve a fetal mosaicism question. Interpretation depends on the actual findings, cell populations assessed and follow-up investigation. The key biological distinction is between evidence about placental tissue and evidence that directly clarifies the fetal chromosome constitution.
Apply it
Cell-free DNA screening is high chance and CVS finds mosaicism. Explain why these results can share a placental explanation and why amniotic-fluid testing may be discussed to assess whether the fetus shares the chromosome change.
Common pitfall: Two concordant results are not automatically independent confirmation when both reflect placental biology. Equally, placental mosaicism must not simply be assumed to exclude fetal involvement.
Prenatal Screening Ontario — Non-Invasive Prenatal Testing · Prenatal Screening Ontario — Chorionic Villus Sampling · Prenatal Screening Ontario — Amniocentesis
51.Why can normal prenatal genetic testing leave an ultrasound question unresolved?
Ultrasound evaluates fetal structure, while chromosome and molecular tests assess specified genetic changes. These are complementary sources of evidence rather than interchangeable reassurance. A normal result from one genetic assay does not explain every structural abnormality or exclude all genetic and non-genetic causes. The next investigation should follow the observed phenotype and the assay's boundaries. Distinguish an established structural finding from a risk marker and from a laboratory diagnosis before describing what has been excluded.
Apply it
A structural anomaly is seen after a low-chance cell-free DNA result. Explain that the screen addressed selected chromosome risks, then use the anomaly and clinical assessment to discuss imaging and diagnostic testing options relevant to that finding.
Common pitfall: A low-chance chromosome screen cannot overrule an observed structural abnormality. A normal microarray also does not exclude every sequence-level cause or non-genetic developmental mechanism.
Prenatal Screening Ontario — Non-Invasive Prenatal Testing · NHS GeNotes — Microarray · CBGC — Exam Content Outline
52.Which prenatal test addresses a known familial sequence variant?
When a family's disease-causing sequence variant is established, the prenatal question may be whether the fetus inherited that specific variant. Obtaining CVS or amniotic-fluid material does not answer this automatically; the laboratory must perform an appropriate targeted analysis. Standard chromosome screening or a normal microarray generally does not exclude a small familial sequence change. Before testing, establish the familial result, inheritance model and what a positive result can and cannot predict about clinical expression.
Apply it
Both parents carry known pathogenic variants in the same recessive gene. Explain why a normal chromosome screen does not settle the fetal disease risk and coordinate diagnostic sampling with analysis of the relevant familial variants.
Common pitfall: Normal chromosomes do not imply absence of a monogenic disorder. Even definitive inheritance information may not precisely predict severity when the condition has variable expression.
Prenatal Screening Ontario — Chorionic Villus Sampling · Prenatal Screening Ontario — Amniocentesis · NHS GeNotes — Microarray · NHS GeNotes — Autosomal recessive inheritance
53.How should prenatal options be connected to a client's values?
Prenatal information can serve different goals, including preparation, clarification of uncertainty and decisions about pregnancy care. Counselling should establish what the client hopes to learn, explain the relevant screening and diagnostic boundaries, and explore how possible results would affect their choices. A decision to accept screening does not imply consent to diagnostic sampling or a particular pregnancy outcome. Shared decision-making combines accurate clinical information with the client's values, circumstances and tolerance for uncertainty.
Apply it
A client wants information to prepare for birth but declines invasive testing. Explore the goal, explain what available screening can establish and respect the informed choice without assuming that information seeking commits the client to another intervention.
Common pitfall: Presenting one reproductive outcome as the purpose of prenatal testing undermines informed choice. Preferences can change, so an earlier decision should not substitute for current consent.
Core Competencies for Genetic Counsellors in Canada 2025 · Prenatal Screening Ontario — Non-Invasive Prenatal Testing
Genetic Counsellingnot stated
54.How does contracting make a counselling session more useful?
Contracting establishes a shared understanding of the session's purpose, the client's concerns and what can realistically be addressed. It brings the counsellor's clinical responsibilities together with the client's priorities rather than assuming they coincide. Clarifying expectations early can reveal that a request for testing actually reflects a need for risk explanation, emotional support or help communicating with relatives. The agreed agenda remains flexible as new concerns arise, while preserving space for essential information and informed decisions.
Apply it
A referral requests test consent, but the client mainly fears blame from relatives. Acknowledge both issues, agree on the session's priorities and explain how discussing the family concern can support rather than bypass the testing decision.
Common pitfall: A standard information script is not a shared agenda. Contracting also does not require promising answers or outcomes that the available clinical evidence cannot provide.
Core Competencies for Genetic Counsellors in Canada 2025 · CBGC — Exam Content Outline
55.How does teach-back assess understanding without shaming the client?
Teach-back asks a client to explain key information in their own words so the clinician can assess how clearly it was communicated. It is framed as a check on the explanation, rather than a test of intelligence or memory. If the explanation reveals a misunderstanding, the clinician rephrases the information and checks again. Focus on the decision-relevant message, such as what a screen-positive result means or which next step the client has chosen, rather than demanding exact technical wording.
Apply it
After explaining a VUS, say that you want to check your explanation and ask the client how they would describe the result to a relative. Re-explain if they describe it as a confirmed diagnosis.
Common pitfall: Asking whether everything is understood invites agreement without demonstrating comprehension. Correcting the client harshly turns a communication check into a performance test and can inhibit further questions.
56.What distinguishes informed choice from directive counselling?
An informed choice combines relevant understanding, a voluntary decision and alignment with the client's values. The counsellor explains benefits, limitations, uncertainties and alternatives, explores preferences and corrects material misconceptions. Supporting autonomy does not mean withholding useful clinical interpretation or leaving the client alone with a difficult choice. Directive pressure arises when the counsellor substitutes personal values or a preferred outcome for the client's decision, particularly when several medically reasonable options carry different personal consequences.
Apply it
A client declines an optional predictive test after accurately explaining its implications. Explore any remaining concerns and document the informed decision rather than treating disagreement with the counsellor's personal preference as evidence of failed understanding.
Common pitfall: Autonomy is not achieved by merely listing options. Equally, accurate risk explanation and checking misconceptions are compatible with autonomy and do not inherently impose a decision.
57.How does cultural humility improve genetic counselling decisions?
Cultural humility requires recognising the limits of one's assumptions and asking how the client understands illness, inheritance, family roles and decision-making. Shared ancestry, language or religion does not establish a uniform set of values. Accessible communication may require language support, different explanatory approaches or attention to practical barriers. The aim is to understand the individual's context and support a voluntary decision, while maintaining accurate information and checking that the client's own perspective remains represented.
Apply it
A client asks to include an elder in discussions. Explore the desired role and communication preferences, arrange appropriate support and continue checking the client's understanding and voluntary agreement rather than assuming a fixed cultural decision-making rule.
Common pitfall: Assigning preferences from group identity replaces inquiry with stereotyping. Cultural responsiveness also does not justify assuming that a family member may provide consent on the client's behalf.
58.How should grief affect the pace and content of counselling?
Grief can affect attention, information processing and the meaning a client assigns to genetic results. Support begins with acknowledging the loss and exploring the person's immediate needs, supports and functioning. Information can be paced, prioritised and revisited rather than delivered as one uninterrupted technical explanation. Grief should not be forced into a fixed sequence of stages. Persistent severe distress or impaired functioning warrants assessment of support needs and appropriate additional care without automatically labelling every strong emotional response pathological.
Apply it
After a pregnancy loss, a client repeatedly loses track of recurrence information. Pause to acknowledge the loss, identify the most urgent question, provide a manageable explanation and arrange an opportunity to revisit details when useful.
Common pitfall: More detail does not necessarily improve understanding during acute distress. Expecting a universal timetable or stage sequence can misinterpret normal variation and weaken supportive communication.
Core Competencies for Genetic Counsellors in Canada 2025 · CBGC — Exam Content Outline
59.How can family benefit be pursued while respecting confidentiality?
Genetic results can have implications for relatives, but shared biological relevance does not automatically authorise disclosure of a client's identifiable information. Discuss who may benefit, what information would be useful and how the client wishes to communicate it. Practical support can include a clear family letter and explanation of targeted testing. When disclosure concerns become complex, distinguish the ethical interests involved from the actual consent and legal framework rather than inventing an unrestricted duty or an absolute rule.
Apply it
A client wants relatives to benefit from a pathogenic result but fears difficult conversations. Offer help developing an accurate family message and discuss consent for any direct communication instead of contacting relatives automatically.
Common pitfall: Familial relevance is not blanket permission to share a report. Conversely, confidentiality does not prevent helping a consenting client communicate information that could support relatives' informed choices.
Core Competencies for Genetic Counsellors in Canada 2025 · NCI — Cancer Genetics Risk Assessment and Counseling (PDQ)
60.What protections and exceptions does Canada's Genetic Non-Discrimination Act establish?
Canada's Genetic Non-Discrimination Act prohibits specified demands to undergo a genetic test or disclose its results as a condition of providing goods or services, entering or continuing a contract, or offering particular terms. It also addresses collection, use and disclosure of genetic test results without written consent in the covered activities. The Act contains healthcare-practitioner and research exceptions. Interpret the precise activity and statutory wording rather than promising that every use of genetic information is prohibited in every setting.
Apply it
A client is told a new service contract requires disclosure of an existing genetic test result. Identify the covered contractual demand and explain the Act's relevant prohibition, while distinguishing this situation from testing used in clinical care.
Common pitfall: The Act does not make all clinical genetic testing unlawful or establish universal genetic privacy worldwide. Written-consent provisions and express exceptions require attention to the actual statutory setting.
Department of Justice Canada — Genetic Non-Discrimination Act
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Separate transmission probability, carrier probability, penetrance and present phenotype before calculating risk.
- Write Bayesian branches and screening denominators explicitly; label assumptions about detection, specificity, prevalence and age.
- Recognise representative phenotypes and connect their mechanisms to investigation and care: Marfan syndrome, hypertrophic cardiomyopathy, cystic fibrosis, 22q11.2 deletion syndrome, Down syndrome, PKU, BRCA-associated susceptibility and Lynch syndrome.
- Match the suspected mechanism to the specimen, assay and variant classes actually assessed.
- Distinguish pathogenic results, uncertain variants, true negatives and uninformative negatives before discussing consequences for relatives.
- Compare prenatal procedures by gestational timing, biological source, analytical scope and additional pregnancy-loss risk; distinguish fetal inheritance from maternal metabolic exposure.
- Practise Canadian client-centred counselling, confidentiality and the specific statutory boundaries of genetic non-discrimination protections.
- Use the full official outline to extend study beyond this selection, including additional disorders and management, imaging, embryology, reproductive technologies and pregnancy-loss investigations.
A practical preparation plan
1. Map the full scope
Read the currently linked CBGC Exam Content Outline and map each numbered competency to training notes. Keep its June 2018 content revision separate from its December 2025 name update. Mark topics absent from this selective guide for additional study.
2. Build mechanism-to-test comparisons
Compare sequence changes, dosage changes, balanced rearrangements, imprinting abnormalities and mosaicism. For each, record an informative specimen, an appropriate analysis and one result that would leave the mechanism unresolved.
3. Work conditional risks by hand
Practise recessive sibling risks, transmission with penetrance, negative-test Bayesian updates and screening two-by-two tables. State the denominator and assumptions before calculating, then translate the result into a sentence a client could use.
4. Review results as counselling decisions
For each result category, explain what is established, what remains uncertain, whether relatives have an informative test target and which personal or family findings still matter. Include a teach-back check and a values-based discussion.
5. Use the learning test diagnostically
Complete the 20 drills before reading explanations. For each error, identify the missed cue and explain why each alternative fails. Revisit the relevant official competency and factual reference; do not interpret this small practice score as a predicted examination result.
6. Consolidate Canadian practice context
Review the 2025 Canadian core competencies alongside cases involving consent, cultural humility, family communication and confidentiality. Learn the Genetic Non-Discrimination Act's covered activities and exceptions, and keep current examination logistics separate from substantive study.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- CBGC — Certification
- CBGC — Exam Preparation Materials
- CBGC — Exam Content Outline
- CBGC — Introduction, Application Pathways and General Information
- Core Competencies for Genetic Counsellors in Canada 2025
- ABGC — About the CGC Credential
- NHGRI — Founder Effect
- NHGRI — Genetic Drift
- NHS Genomics Education — All about mitochondria: Definition and disease
- NHS GeNotes — Mitochondrial DNA testing
- NHS GeNotes — Visual communication aid: Autosomal recessive inheritance
- NHS GeNotes — Autosomal recessive inheritance
- NHS GeNotes — Penetrance
- NHS Genomics Education — Do our genes govern our fate?
- ACMG/AMP — Standards and guidelines for the interpretation of sequence variants
- NHS GeNotes — Visual communication aid: Variants of uncertain significance
- NHGRI — Frameshift Mutation
- NHS GeNotes — Microarray
- NHS GeNotes — Karyotype
- NHS GeNotes — Mosaicism
- NHGRI — Enzyme
- Newborn Screening Ontario — Phenylketonuria
- NCI — Cancer Genetics Risk Assessment and Counseling (PDQ)
- NCI — Genetic Testing for Inherited Cancer Risk
- CDC — Principles of Epidemiology, Lesson 5, Appendix A
- Newborn Screening Ontario — Screen Positive Results
- Prenatal Screening Ontario — Non-Invasive Prenatal Testing
- Prenatal Screening Ontario — Chorionic Villus Sampling
- Prenatal Screening Ontario — Amniocentesis
- AHRQ — Use the Teach-Back Method: Tool 5
- Department of Justice Canada — Genetic Non-Discrimination Act
- Genetic Imprinting
- Archived | Population Genetics and Statistics for Forensic Analysts | Inbreeding | National Institute of Justice
- What are the different ways a genetic condition can be inherited?: MedlinePlus Genetics
- What are genomic imprinting and uniparental disomy?: MedlinePlus Genetics
- Phenylketonuria: MedlinePlus Genetics
- PAH gene: MedlinePlus Genetics
- FBN1-Related Marfan Syndrome - GeneReviews® - NCBI Bookshelf
- Nonsyndromic Hypertrophic Cardiomyopathy Overview - GeneReviews® - NCBI Bookshelf
- Cystic Fibrosis - GeneReviews® - NCBI Bookshelf
- 22q11.2 Deletion Syndrome - GeneReviews® - NCBI Bookshelf
- BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet - NCI
- Genetics of Colorectal Cancer (PDQ®) - NCI
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.